A call for screening MRI as a tool for osteoarthritis clinical trials

Guermazi A, Roemer FW, Jarraya M, Hayashi D (2023)


Publication Type: Journal article

Publication year: 2023

Journal

DOI: 10.1007/s00256-023-04354-z

Abstract

Conventional radiography is the most commonly used imaging modality for the evaluation of osteoarthritis (OA) in clinical trials of disease-modifying OA drugs (DMOADs). Unfortunately, radiography has many shortcomings as an imaging technique to meaningfully assess the pathological features of OA. In this perspective paper, we will describe the reasons why radiography is not an ideal tool for structural OA assessment and why magnetic resonance imaging (MRI) should be preferred for such purposes. These shortcomings include a lack of reproducibility of radiographic joint space measurements (if conducted without using a standardized positioning frame), a lack of sensitivity and specificity, an insufficient definition of disease severity, a weak association of radiographic structural damage and pain, a lack of ability to depict many faces of OA, and incapability to depict diagnoses of exclusion. MRI offers solutions to these limitations of radiography. Several different phenotypes of OA have been recognized and it is important to recruit appropriate patients for specific therapeutic approaches in DMOAD trials. Radiography does not allow such phenotypical stratification. We will explain known hurdles for widespread deployment of MRI at eligibility screening and how they can be overcome by technological advances and the use of simplified image assessment.

Involved external institutions

How to cite

APA:

Guermazi, A., Roemer, F.W., Jarraya, M., & Hayashi, D. (2023). A call for screening MRI as a tool for osteoarthritis clinical trials. Skeletal Radiology. https://doi.org/10.1007/s00256-023-04354-z

MLA:

Guermazi, Ali, et al. "A call for screening MRI as a tool for osteoarthritis clinical trials." Skeletal Radiology (2023).

BibTeX: Download